Metastatic Alveolar Soft Part Sarcoma Responsive to Pazopanib after Progression through Sunitinib and Bevacizumab: Two Cases
Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma with a propensity for lung metastases and indolent progression. ASPS is not responsive to chemotherapy, but there are case reports and small series describing benefit from drugs targeting the VEGF pathway. These drugs include sunitinib,...
Main Authors: | William L. Read, Felicia Williams |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2016-10-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/450545 |
Similar Items
-
Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis
by: Que Y, et al.
Published: (2018-07-01) -
Pazopanib in the management of advanced soft tissue sarcomas
by: Cranmer LD, et al.
Published: (2016-06-01) -
Alveolar soft part sarcoma: progress toward improvement in survival? A population-based study
by: Tomohiro Fujiwara, et al.
Published: (2022-08-01) -
Alveolar soft part sarcoma of the forearm
by: B. Asokan, et al.
Published: (2017-09-01) -
Alveolar soft-part sarcoma of the orbit
by: Rose Anna, et al.
Published: (2011-01-01)